← Leaderboards
Richard E Pratley
Adventhealth Orlando
$7,581,312
Attributed
$16,921,346
Total exposure
29
Grants
22
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,921,346 · 29
By mechanism
R01$6,715,106 · 3
U01$5,940,855 · 4
DP3$1,911,815 · 1
P20$1,269,433 · 4
M01$635,103 · 16
R21$449,034 · 1
Top collaborators
- Christopher E Forsmark7 shared
- Steven J Hughes7 shared
- Yogish C. Kudva6 shared
- Naomi Sage Chaytor5 shared
- Michael R Rickels5 shared
- Robert J Henderson4 shared
- Anna Casu3 shared
- Vernon M. Chinchilli2 shared
Others in their field
Top investigators on “Diabetes Mellitus”
- Jeffrey P Krischer · University Of South Florida$608,226,434
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$177,347,135
- John M Lachin · George Washington University$155,262,668
- David M Nathan · Massachusetts Institute Of Technology$142,806,023
- Judith S Hochman · New York University School Of Medicine$100,149,457
- Jose A Luchsinger · Columbia University Health Sciences$75,551,718
Research focus
Diabetes MellitusInsulinResearch PersonnelResourcesPreventionUnited States National Institutes Of HealthInsulin-Dependent Diabetes MellitusClinical ResearchFundingParticipantSamplingGrantInstitutionCohortFatty Acid Glycerol EstersMetabolicSourceComputer Retrieval Of Information On Scientific Projects DatabaseOgttResponseDiagnosisGlucosePreventMeasurement
Grant awards (45)
Ketone Monitoring Approaches for DKA Risk Mitigation in People with T1D on Adjunctive SGLT2 Inhibitors (KARMA)$2,477,577
U01 · FY2025 · DK · contact PI
Care partner-assisted ImplementatiOn of Patch HybrId Closed Loop Insulin Delivery for Older Adults with T1D (COPILOT)$2,345,176
R01 · FY2025 · DK
Diabetes RElated to Acute Pancreatitis and its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (DREAM-ON)$690,764
R01 · FY2025 · DK
Continuation of Type 1 Diabetes in Acute Pancreatitis Consortium â UF Health and AdventHealth Combined Clinical Center$452,769
U01 · FY2025 · DK
The Chronic Pancreatitis Clinical Research Consortium$435,853
U01 · FY2025 · DK
Advanced Insulin Delivery to Reduce Impaired Awareness of Hypoglycemia in a T1D Cohort (AIDRIAHT1C)$328,315
U01 · FY2025 · DK · contact PI
Diabetes RElated to Acute Pancreatitis and its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics (DREAM-ON)$918,188
R01 · FY2024 · DK
Advanced Insulin Delivery to Reduce Impaired Awareness of Hypoglycemia in a T1D Cohort (AIDRIAHT1C)$850,910
U01 · FY2024 · DK · contact PI
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers$195,129
U01 · FY2024 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$239,044
R01 · FY2023 · DK
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers$197,394
U01 · FY2023 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$565,751
R01 · FY2022 · DK
Advanced Insulin Delivery to Reduce Impaired Awareness of Hypoglycemia in a T1D Cohort (AIDRIAHT1C)$394,327
U01 · FY2022 · DK · contact PI
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers$197,394
U01 · FY2022 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$638,470
R01 · FY2021 · DK
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers$198,491
U01 · FY2021 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$657,345
R01 · FY2020 · DK
Type 1 Diabetes in Acute Pancreatitis Consortium - Clinical Centers$212,696
U01 · FY2020 · DK
A Randomized Cross-Over Trial Evaluating Automated Insulin Delivery Technologies on Glycemic Outcomes and Quality of Life in Older Adults with Type 1 Diabetes$660,368
R01 · FY2019 · DK
Accelerating Solutions to Optimize Glycemic Control and Weight Management In Young Adults with Type 1 Diabetes$1,911,815
DP3 · FY2017 · DK
IMPAIRED ADIPOGENESIS IN INSULIN RESISTANCE: PILOT CLINICAL AMP IN VITRO STUDIES$163,461
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: EFFECTS OF PIOGLITAZONE ON INCRETIN AXIS IN PTS W TYPE 2 DIABETE$153,191
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: EFFECTS OF SITAGLIPTIN ON BONE TURNOVER IN PTS WITH TYPE 2 DIABE$71,033
M01 · FY2010 · RR · contact PI
Impaired adipogenesis in insulin resistance: pilot clinical and in-vitro studies$38,962
R21 · FY2010 · DK · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$7,702
M01 · FY2010 · RR · contact PI
WEIGHT LOSS & ASTHMA$323,873
P20 · FY2009 · RR · contact PI
Impaired adipogenesis in insulin resistance: pilot clinical and in-vitro studies$188,125
R21 · FY2009 · DK · contact PI
CLINICAL TRIAL: EFFECTS OF PIOGLITAZONE ON INCRETIN AXIS IN PTS W TYPE 2 DIABETE$30,774
M01 · FY2009 · RR · contact PI
IMPAIRED ADIPOGENESIS IN INSULIN RESISTANCE$24,247
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: EFFECTS OF SITAGLIPTIN ON BONE TURNOVER IN PTS WITH TYPE 2 DIABE$21,450
M01 · FY2009 · RR · contact PI
NON-INVASIVE GLUCOSE MONITORING USING EXHALED BREATH CONDENSATE$10,259
M01 · FY2009 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$10,259
M01 · FY2009 · RR · contact PI
WEIGHT LOSS & ASTHMA$318,492
P20 · FY2008 · RR · contact PI
Impaired adipogenesis in insulin resistance: pilot clinical and in-vitro studies$221,947
R21 · FY2008 · DK · contact PI
NON-INVASIVE GLUCOSE MONITORING USING EXHALED BREATH CONDENSATE$14,988
M01 · FY2008 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$7,493
M01 · FY2008 · RR · contact PI
WEIGHT LOSS & ASTHMA$297,039
P20 · FY2007 · RR · contact PI
ADIPOSE TISSUE MCP-1 AND MIF: ROLE IN OBESITY-ASSOCIATED INFLAMMATION$48,080
M01 · FY2007 · RR · contact PI
NATURAL HISTORY STUDY OF THE DEVELOPMENT OF TYPE I DIABETES$12,975
M01 · FY2007 · RR · contact PI
WEIGHT LOSS & ASTHMA$330,029
P20 · FY2006 · RR · contact PI
EFFECTS OF LAF237 ON MAX INSULIN SECRETION IN PTS WITH TYPE 2 DIABETES$39,366
M01 · FY2006 · RR · contact PI
ADIPOSE TISSUE MCP-1 AND MIF: RELATION TO GLUCOSE TOLERANCE, INSULIN ACTION$3,192
M01 · FY2006 · RR · contact PI
EFFECTS OF LAF237 ON MAX INSULIN SECRETION IN PTS WITH TYPE 2 DIABETES$16,633
M01 · FY2005 · RR
Insulin Secretory Defects in Pima Indians at High Risk for NIDDM$0
Z01 · FY2000 · DK
Cross-sectional and Longitudinal Study of "pre-diabetes" in the Pima Indians$0
Z01 · FY2000 · DK